MDoutlook OncoPoll ASCO 2015 – NSCLC and Immune Checkpoint Inhibitors

MDoutlook celebrates its 8th consecutive year of syndicated research gauging the clinical impact of new data presented at ASCO 2015. Building on over 30 analyses since 2008, MDoutlook today releases the first analysis in a new series covering solid and liquid tumors.

This OncoPoll™ focuses on the continued evolution of targeted therapy, and especially on the clinical impact of exciting new updates for Immune Checkpoint Inhibitors. Our most recent research from 125 global oncologists managing NSCLC patients uncovers that:

  • For cases of NSCLC without driver mutations, treatment with the anti-PD-1/PD-L1 antibodies is expected to become the main 2nd line treatment option
  • These anti-PD-1/PD-L1 antibodies WILL be included in the treatment of ALK+ or EGFR-mutated NSCLC, albeit in 1 later line of therapy (primarily starting in 3rd line)
  • Combining the anti-PD-1/PD-L1 antibodies with the anti-CTLA-4 antibody ipilimumab is seen as a promising approach that will further impact treatment paradigms in the future
  • Even at today’s prices, physicians see good value in using the anti-PD-1/PD-L1 antibodies for NSCLC

Download your complimentary copy of the MDoutlook 2015 ASCO Syndicated NSCLC OncoPoll through the link.

MDoutlook continues its commitment to the cancer community to provide meaningful, timely and relevant insight. As in previous years, we work with Oncology Business Review to share this important research widely.

MDoutlook is disease intelligence redefined. Governed by top ThoughtLeaders and driven by in-house MD and PhD medical experts, MDoutlook® is powered by a proprietary, global cloud-based disease intelligence platform accessing 1M+ multi-disciplinary treaters of complex diseases, including cancer, hematology, auto-immune diseases.

Email or phone (+1.404.496.4136 / 888.3outlook) to discuss how MDoutlook can answer your disease intelligence needs.

Unlock Total Oncology Intelligence

MDoutlook Total Oncology Intelligence Sq

Since 2008, MDoutlook has built the largest panel of cancer treaters in the world. With more than 85,000 cancer treaters verified and profiled, MDoutlook uniquely identifies and targets oncologists and other physicians dedicated to the management of cancer.

MDoutlook has developed a suite of offerings built on this proprietary oncology panel to address the needs of clinical, commercial and business development functions at life science organizations.

Unlock this Total Oncology Intelligence to answer your questions.

Our team brings the experience of over 400 cancer intelligence projects to the bespoke and syndicated insight our clients require. Access the latest fact sheet on our Total Oncology Intelligence capabilities here.

Contact us to discuss how MDoutlook can deliver on your disease intelligence needs.

Understand the ThoughtLeaders Who Really Impact

Built upon years of experience and appreciating the multi-factorial complexity of identifying and engaging ThoughtLeaders, MDoutlook has developed robust algorithms to capture all attributes of a ThoughtLeader’s impact on the market.

MDoutlook delivers 360° profiles of identified ThoughtLeaders, uniquely meshing public and proprietary data. Through our exclusive ThoughtLeader Attribute Dial™, clients can rank ThoughtLeaders targeted by their internal stakeholder and desired type of engagement with the ThoughtLeader. Innovative visualization provides important insights and highlights clusters of relevant collaboration.

Deliverables range from databases and flat files, to data-streams into existing client systems, to accessing MDoutlook’s integrated web-based platform.

Download the latest fact sheet on our ThoughtLeader Intelligence capabilities here.

Contact us to discuss how MDoutlook can deliver on your disease intelligence needs.

Assessing the Clinical Impact of Market Developments

MDoutlook supports dozens of clients in understanding the real changes in clinical practice.

Driven by a proven methodology, engaging proprietary panels of validated and qualified healthcare providers, our team delivers meaningful insights to life science clients: from large to small, from mainstream pharma to biotech, and from medicine to technology and everything in between.

Download the latest fact sheet on our Clinical Impact Intelligence capabilities here.

Contact us to discuss how MDoutlook can deliver on your disease intelligence needs.